INOVIO PHARMACEUTICALS, INC.: net intangible assets excluding goodwill

What this measure means

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

Exact concept: us-gaap:IntangibleAssetsNetExcludingGoodwill. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2010-12-31 to 2023-12-31. The SEC response was captured on 2026-09-20.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Related financial histories

• INOVIO PHARMACEUTICALS, INC.: total assets
• INOVIO PHARMACEUTICALS, INC.: total liabilities
• INOVIO PHARMACEUTICALS, INC.: stockholders equity
• INOVIO PHARMACEUTICALS, INC.: cash and cash equivalents
• INOVIO PHARMACEUTICALS, INC.: net income or loss
• INOVIO PHARMACEUTICALS, INC.: operating cash flow
• INOVIO PHARMACEUTICALS, INC.: capital expenditure payments
• INOVIO PHARMACEUTICALS, INC.: revenue
• INOVIO PHARMACEUTICALS, INC.: contract revenue excluding tax
• INOVIO PHARMACEUTICALS, INC.: financing cash flow
• INOVIO PHARMACEUTICALS, INC.: investing cash flow
• INOVIO PHARMACEUTICALS, INC.: retained earnings or deficit
• INOVIO PHARMACEUTICALS, INC.: basic weighted-average shares
• INOVIO PHARMACEUTICALS, INC.: diluted weighted-average shares
• INOVIO PHARMACEUTICALS, INC.: basic earnings per share
• INOVIO PHARMACEUTICALS, INC.: diluted earnings per share
• INOVIO PHARMACEUTICALS, INC.: income tax expense or benefit
• INOVIO PHARMACEUTICALS, INC.: net property, plant and equipment
• INOVIO PHARMACEUTICALS, INC.: share-based compensation expense
• INOVIO PHARMACEUTICALS, INC.: operating income or loss
• INOVIO PHARMACEUTICALS, INC.: current assets
• INOVIO PHARMACEUTICALS, INC.: interest expense
• INOVIO PHARMACEUTICALS, INC.: current liabilities
• INOVIO PHARMACEUTICALS, INC.: goodwill carrying amount
• INOVIO PHARMACEUTICALS, INC.: net finite-lived intangible assets
• INOVIO PHARMACEUTICALS, INC.: net current accounts receivable
• INOVIO PHARMACEUTICALS, INC.: operating expenses
• INOVIO PHARMACEUTICALS, INC.: research and development expense
• INOVIO PHARMACEUTICALS, INC.: common shares outstanding
• INOVIO PHARMACEUTICALS, INC.: cash including restricted cash
• INOVIO PHARMACEUTICALS, INC.: additional paid-in capital
• INOVIO PHARMACEUTICALS, INC.: accumulated other comprehensive income or loss
• INOVIO PHARMACEUTICALS, INC.: total equity including noncontrolling interests
• INOVIO PHARMACEUTICALS, INC.: operating lease right-of-use asset
• INOVIO PHARMACEUTICALS, INC.: operating lease liability
• INOVIO PHARMACEUTICALS, INC.: gross property, plant and equipment
• INOVIO PHARMACEUTICALS, INC.: accumulated depreciation on property, plant and equipment
• INOVIO PHARMACEUTICALS, INC.: other noncurrent assets
• INOVIO PHARMACEUTICALS, INC.: other noncurrent liabilities
• INOVIO PHARMACEUTICALS, INC.: accrued current liabilities
• INOVIO PHARMACEUTICALS, INC.: prepaid expenses and other current assets
• INOVIO PHARMACEUTICALS, INC.: current contract liabilities
• INOVIO PHARMACEUTICALS, INC.: net deferred tax assets
• INOVIO PHARMACEUTICALS, INC.: net deferred tax liabilities
• INOVIO PHARMACEUTICALS, INC.: pre-tax income or loss from continuing operations
• INOVIO PHARMACEUTICALS, INC.: profit or loss including noncontrolling interests
• INOVIO PHARMACEUTICALS, INC.: comprehensive income or loss
• INOVIO PHARMACEUTICALS, INC.: net income available to common stockholders
• INOVIO PHARMACEUTICALS, INC.: general and administrative expense
• INOVIO PHARMACEUTICALS, INC.: depreciation expense
• INOVIO PHARMACEUTICALS, INC.: amortization of intangible assets
• INOVIO PHARMACEUTICALS, INC.: nonoperating interest expense
• INOVIO PHARMACEUTICALS, INC.: other nonoperating income or expense
• INOVIO PHARMACEUTICALS, INC.: current income tax expense or benefit
• INOVIO PHARMACEUTICALS, INC.: deferred income tax expense or benefit
• INOVIO PHARMACEUTICALS, INC.: interest paid, net
• INOVIO PHARMACEUTICALS, INC.: proceeds from issuing common stock
• INOVIO PHARMACEUTICALS, INC.: change in accounts receivable

Inspect the source

Entity

INOVIO PHARMACEUTICALS, INC. / CIK 0001055726

Captured

2026-09-20T05:17:43.559Z

SEC response SHA-256

9bfa830827e08b2d190e6d0b4ce0274a3c0d8852b6e536b16b5cfeadcaa54cf9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001055726.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))